Hana M?llerov?1, Jadwiga Wedzicha2, Marc Decramer3
and Paul Jones4,5
Epidemiology, GSK R&D, Uxbridge, United Kingdom, 2National
Heart and Lung Institute, Imperial College, London, United Kingdom,
3University Hospital, University Hospital, Leuven, Belgium,
4Respiratory Franchise, GSK, Uxbridge, United Kingdom, 5Institute for
Infection and Immunity, St George's, University, London, United Kingdom
We describe the change in COPD outcomes over time in a
in primary care.
The ACCESS (Assessment of Comorbidities in COPD in European Symptomatic
Subjects; 115058 study; NCT01516528) was an observational study that
prospectively recruited COPD patients across Europe. There were minimal
exclusion criteria, but a significant smoking history was required.
COPD outcomes collected over 24 months included COPD Assessment Test
(CAT), COPD exacerbations, and airflow limitation. Change over time
(from screening for FEV1 [L]; from baseline for CAT) was described as a
difference. A mixed linear model was used to explain the change in CAT
score (annual) with baseline traits (country, age, gender, CVD
comorbidity, smoking, exacerbations prior to study, CAT score) and
exacerbations during the study period as covariates.
2887 COPD patients (mean age: 66yrs; 30% females; mean of 59% FEV1%
predicted, 0.61 exacerbations/person-year) had at screening FEV1 mean
of 1.68L [95% CI: 1.66;1.71]; Mean change in FEV1 was 30.6mL
(95%CI:12.8;48.4; N=2208) at 12M and -55.6mL [95%CI:-73.9;-37.3;N=1894]
12M to 24M . At baseline, mean CAT score was 15.0 [95%CI: 14.7;15.3].
Mean change in CAT score was mean of -0.04 score [95%CI: - -0.28, 0.21;
N=2646] at 12M and 1.01 [95%CI: 0.74; 1.27; N=2342] at 24 M. Change in
CAT score change was predicted both by FEV1 and by CAT score at
baseline and exacerbations during the study.
In this large, well-defined, primary care cohort of COPD patients, a
wide variation in disease progression was observed, with sustained
worsening on average. CAT score change over two years was predicted by
exacerbation frequency during the follow-up and disease severity traits.
Image : http://a360-wp-uploads.s3.amazonaws.com/...